Armata Pharmaceuticals (ARMP) Capital Expenditures (2013 - 2026)

Armata Pharmaceuticals has disclosed Capital Expenditures across 14 years of filings, most recently posting $63000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $63000.0, down 36.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $506000.0 (down 70.72% YoY), and the FY2025 annual result was $542000.0, down 71.15% from the prior year.
• Capital Expenditures came in at $63000.0 for Q1 2026 at Armata Pharmaceuticals, up from $52000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $3.5 million in Q3 2023 to a low of -$455000.0 in Q4 2022.
• The 5-year median for Capital Expenditures is $242000.0 (2025), against an average of $755235.3.
• Across the five-year window, Capital Expenditures slumped 299.56% in 2022 and soared 751.69% in 2023, its largest moves.
• Armata Pharmaceuticals' Capital Expenditures stood at -$455000.0 in 2022, then soared by 627.47% to $2.4 million in 2023, then slumped by 103.21% to -$77000.0 in 2024, then jumped by 167.53% to $52000.0 in 2025, then climbed by 21.15% to $63000.0 in 2026.
• The last three Capital Expenditures figures came in at $63000.0 (Q1 2026), $52000.0 (Q4 2025), and $242000.0 (Q3 2025), per Business Quant data.